|Clone||EPR5701 + 34ßE12|
|Isotype||IgG + IgG1|
|Product Type||Primary Antibodies|
The p63 protein, a homologue of the tumour-suppressor p53, is highly expressed in the nuclei of basal or progenitor layer of many epithelial tissues. p63 is detected in prostate basal cells in normal prostate glands and PIN. Other markers for basal cells are high molecular cytokeratins (CK 1, 5, 10 and 14), which can be labelled with HMW CK clone 34ßE12. In prostate adenocarcinoma basal cells disappear and staining with both p63 and HMW CK fails. Thus the combination of p63 and HMW CK is a useful tool as differential markers for benign prostate glands and adenocarcinoma (negative marker). nuclear p63 and cytoplasmic high molecular weight cytokeratins.
Immunogen: Recombinant human p63 protein (aa 1-203) and cytokeratin extract of human stratum corneum
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005), but also other staining systems including anti-rabbit IgG will be suitable.
Species Reactivity: Human
Incubation Time: 30-60 min
Working Concentration: (RTU) neat
Pre-Treatment: Use formalin-fixed and paraffin-embedded sections; Retrieval conditions: Unmasking fluid T, TEC buffer (Tris/EDTA/Citrate) pH 8 (Art. No. DE005) in a pressure cooker at 100°C 20-40 minutes
Positive Control: Normal prostate tissue or skin
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
1. Signoretti S., Waltregny D., Dilks J., Isaak B., Lin D., Garraway L., et al. (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J. Pathol. 157; 1769-1775. 2. Weinstein M.H., Signoretti S., and Loda M. (2002) Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 15(12); 1302-1308 3. Yang X.J., Lecksell K., Gaudin P., and Epstein J.I. (1999) Rare expression of high-molekular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am. J. Surg. Pathol. 23(2); 147-152. 4. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec;35(12):1462-8. 5. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005 Feb;123(2):231-6.